产品
编 号：F035997
分子式：C26H46NNaO7S
分子量：539.7
分子式：C26H46NNaO7S
分子量：539.7
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
200
In-stock
10mg
304
In-stock
25mg
600
In-stock
50mg
880
In-stock
100mg
1280
In-stock
结构图
CAS No: 110026-03-4
产品详情
生物活性：
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
体内研究：
Taurodeoxycholate (0.5 mg/kg；静脉注射；一次) 对患有脓毒症的 C57BL/6N 小鼠提供保护，但不能保护患有脓毒症的 TGR5 KO 小鼠。Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:0.5 mg/kg
Administration:Intravenous injection, 30 min or 24 h after LPS injection
Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.
体外研究：
Taurodeoxycholate 在健康个体中的中位血浆浓度为 33.9 nM。Taurodeoxycholate 抑制 N-3H-甲基东莨菪碱与 M3 毒蕈碱受体的结合乙酰胆碱的 IC50 为 170 μM。牛磺脱氧胆酸盐 (0.05-1.00 mM；1-6 天) 刺激肠上皮细胞增殖。 Taurodeoxycholate (0.05-1.00 mM；24 h) 诱导细胞周期的S期浓度显著增加和G1期浓度显著降低，增加c-myc IEC-6细胞蛋白和mRNA的表达。
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. Taurodeoxycholic acid sodium hydrate activates the S1PR2 pathway in addition to the TGR5 pathway.
体内研究：
Taurodeoxycholate (0.5 mg/kg；静脉注射；一次) 对患有脓毒症的 C57BL/6N 小鼠提供保护，但不能保护患有脓毒症的 TGR5 KO 小鼠。Animal Model:C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis
Dosage:0.5 mg/kg
Administration:Intravenous injection, 30 min or 24 h after LPS injection
Result:Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice.
体外研究：
Taurodeoxycholate 在健康个体中的中位血浆浓度为 33.9 nM。Taurodeoxycholate 抑制 N-3H-甲基东莨菪碱与 M3 毒蕈碱受体的结合乙酰胆碱的 IC50 为 170 μM。牛磺脱氧胆酸盐 (0.05-1.00 mM；1-6 天) 刺激肠上皮细胞增殖。 Taurodeoxycholate (0.05-1.00 mM；24 h) 诱导细胞周期的S期浓度显著增加和G1期浓度显著降低，增加c-myc IEC-6细胞蛋白和mRNA的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备